Summary of adverse events (AEs) through Week 16
| Patients, n (%) | Deucravacitinib n=332 | Placebo n=165 | Apremilast n=168 |
| Any AEs | 176 (53.0) | 70 (42.4) | 93 (55.4) |
| Severe AEs | 5 (1.5) | 7 (4.2) | 5 (3.0) |
| Serious AEs | 7 (2.1) | 9 (5.5) | 4 (2.4) |
| AEs leading to treatment discontinuation | 6 (1.8) | 7 (4.2) | 10 (6.0) |
| Most common AEs (≥5% in any arm) | |||
| Nasopharyngitis | 21 (6.3) | 7 (4.2) | 14 (8.3) |
| Upper respiratory tract infection | 21 (6.3) | 6 (3.6) | 3 (1.8) |
| Headache | 16 (4.8) | 5 (3.0) | 17 (10.1) |
| Diarrhea | 13 (3.9) | 6 (3.6) | 17 (10.1) |
| Nausea | 7 (2.1) | 4 (2.4) | 19 (11.3) |